Novartis to buy breast cancer drug candidate from Synnovation

Core Viewpoint - Novartis has agreed to acquire the breast cancer drug candidate SNV4818 from Synnovation Therapeutics for an upfront payment of $2 billion, with an additional $1 billion contingent on further development achievements [1][2]. Group 1: Acquisition Details - The acquisition involves an upfront payment of $2 billion and potential additional payments of up to $1 billion based on development milestones [1]. - SNV4818 is classified as a selective PI3K inhibitor, representing a new treatment approach for HR positive/HER2 negative breast cancer and potentially other solid tumors [2].